The IDEAS Study will meet the enrollment goal for Aim 1 on July 31, 2017. Study enrollment will continue to enable completion of Aim 2 of the study which seeks to assess the impact of amyloid PET on hospital admissions and emergency room visits.

**AIM 1**
Registration, pre-PET visit, and 90 day post-PET follow-up visit (participant projection 11,050)

**AIM 2**
Study enrollment continues. No 90 day post-PET visit or 90 day data submission required. (participant projection 18,488)

---

**Important Reminders**

- There is no 90 day post-PET visit (nor data collection) required for participants enrolled after July 31.

- Aim 2 analysis uses patient claims obtained directly from CMS. No action is necessary on the part of the site to facilitate this process.

- Participant death reporting (presently available on the post-PET case report form) will only be collected for Aim 1 enrollment.

- Medicare Advantage (MA) participants may continue to be enrolled in the Study for Aim 2.

- All Aim 1 participants will continue to be followed through to the 90 day post-PET visit and data collection.

- Each Dementia Specialist has an enrollment cap total of 160 cases in Aim 1 and 90 cases in Aim 2 for a total of 250 cases in the entire study.